CBRS enters its June 12 earnings report in a genuinely unusual position: a wave of fresh analyst initiations has just declared the stock a buy, while the lending market is tightening sharply and short interest jumped more than fourfold in a single session.
The Street launched coverage en masse this week. Ten firms initiated over two days, with every single one landing at Buy, Outperform, or Overweight — a unanimity that is rare even in hot sectors. Morgan Stanley opened with an Overweight and a $250 target. Mizuho and UBS both came in at $300. Citigroup set the high-water mark at $340. The consensus target across all six tracked analysts sits at $293, roughly 29% above Monday's close of $226.82. The bull case centres on Cerebras's partnerships with OpenAI and AWS, its custom silicon positioning in large-model inference, and projected revenue and profit inflection through 2026-27. Bears point to the heavy upfront capital requirements of its cloud and dedicated-capacity model, customer concentration risk, and the very real threat of larger chip makers moving into its niche.
Positioning tells a more complicated story beneath that bullish analyst surface. Borrow availability has tightened dramatically — from around 136% of short interest in late May to just 20.5% now, its tightest reading of the past year. That means only one share remains available to borrow for every five already lent out. Estimated short interest jumped from roughly 1.9 million shares to 8.4 million in a single day on June 9, a 344% one-day move. The cost to borrow, however, has moved in the opposite direction: it has fallen sharply from a peak near 20% in mid-May to just 1.1% now, suggesting that while new shorts are piling in, the borrow itself is not yet difficult or expensive to establish. The ORTEX short score leapt to 67 on June 9 from 56 the day before — the biggest single-day jump in the recent history shown — flagging a meaningful shift in short-side momentum just before the print. Options positioning has also rotated: the put/call ratio has declined steadily from 0.92 in late May to 0.58 this week, its lowest recent reading, implying the options market is now more tilted toward upside calls than at any point in the past month. That divergence — calls dominant, shorts building, availability collapsing — sets up a charged backdrop heading into Thursday's numbers.
Institutional ownership is dominated by the IPO-era investor syndicate. FMR (Fidelity) holds 11.6% of shares, making it the largest institutional holder. Foundation Capital, Benchmark, Eclipse Operations, and Alpha Wave collectively hold another 25%. Notably, all recorded last changes as additions — the post-IPO register is still being built out by public-market buyers. Founders are also still present on the cap table: CEO Andrew Feldman holds 3.4% and co-founder and CTO Sean Lie holds 1.9%. Both sold in mid-May at $185, alongside the COO and Chief Accounting Officer, generating combined proceeds north of $130 million at the lock-up. The stock has since climbed about 23% above that sale price, which will not have gone unnoticed by the newly initiated analysts.
Valuation anchors are limited for a company still burning cash — CBRS carries a negative earnings yield and a price-to-book of nearly 13x, while the EV/EBITDA of 37x reflects forward consensus rather than current profitability. The company has no earnings reaction history to draw on. What Thursday's print will test is whether the revenue trajectory supports the growth story that a ten-firm unanimous-buy initiation has just baked in — and whether availability in the lending market can hold at current levels if the numbers disappoint.
See the live data behind this article on ORTEX.
Open CBRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
